首页> 外国专利> USE OF TRILOSTANE AND ITS DERIVATIVES, OPTIONALLY IN COMBINATION WITH TAMOXIFEN OR RALOXIFENE IN THE TREATMENT OF ESTROGEN-DEPENDENT CANCERS E.G. BREAST, PROSTATE AND UTERUS CANCERS

USE OF TRILOSTANE AND ITS DERIVATIVES, OPTIONALLY IN COMBINATION WITH TAMOXIFEN OR RALOXIFENE IN THE TREATMENT OF ESTROGEN-DEPENDENT CANCERS E.G. BREAST, PROSTATE AND UTERUS CANCERS

机译:曲妥烷及其衍生物的使用,可选地与他莫昔芬或雷洛昔芬联合用于治疗与雌激素有关的癌症,例如乳腺癌,前列腺癌和子宫癌

摘要

Certain steroid compounds which are 2 a -cyano-4 a , 5 a -epoxy-3-oxo steroids notably trilostane, act on specific isoforms of the oestrogen receptor in human and animal cells. The compounds are used to treat certain conditions in hormone-sensitive organs such as but not exclusively breast, prostate, central nervous system, heart, blood vessels and uterus. The invention shows that trilostane and related compounds selectively modulate ligand binding to the oestrogen receptor and in particular to oestrogen receptor beta. Also claimed are particulate forms of these compounds which consist of particles having a mean equivalent sphere volume diameter of 12 žm or less and 90% having a particle size less than 50 žm.
机译:某些类固醇化合物是2 a-氰基-4 a和5 a-环氧-3-氧代类固醇,尤其是三氯噻吨,作用于人和动物细胞中雌激素受体的特定同工型。该化合物用于治疗激素敏感器官的某些病症,例如但不限于乳房,前列腺,中枢神经系统,心脏,血管和子宫。本发明表明,三氯噻酮和相关化合物选择性地调节配体与雌激素受体,特别是与雌激素受体β的结合。还要求保护这些化合物的颗粒形式,其由平均等效球体体积直径为12或更小的颗粒和90%的颗粒小于50的颗粒组成。

著录项

  • 公开/公告号IL150768D0

    专利类型

  • 公开/公告日2003-02-12

    原文格式PDF

  • 申请/专利权人

    申请/专利号IL20000150768

  • 申请日2000-07-25

  • 分类号7C07JA;

  • 国家 IL

  • 入库时间 2022-08-22 00:02:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号